Control group    (DrugBank: -)

3 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis5
46Malignant rheumatoid arthritis28
70Spinal stenosis3

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
5 / 508 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000028960
2021-01-012020-01-09Exploratory study of low-intensity ultrasound in the disease progression of amyotrophic lateral sclerosisExploratory study of low-intensity ultrasound in the disease progression of amyotrophic lateral sclerosis Amyotrophic lateral sclerosisexperimental group:wearable low-intensity ultrasound and Riluzole;control group:ineffective ultrasound and Riluzole;University Affiliated Sixth People's HospitalNULLPending1870Bothexperimental group:20;control group:20;China
2ChiCTR2000035988
2020-10-012020-08-21Exploratory study of wearable low-intensity ultrasound in the disease progression of Amyotrophic lateral sclerosisExploratory study of wearable low-intensity ultrasound in the disease progression of Amyotrophic lateral sclerosis Amyotrophic lateral sclerosisexperimental group:wearable low-intenstiy ultrasound + riluzole;control group:invalid ultrasound + riluzole;Shanghai Sixth People's HospitalNULLPending1870Bothexperimental group:25;control group:25;China
3NCT04518540
(ClinicalTrials.gov)
September 1, 20205/8/2020Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral SclerosisRandomized, Parallel Safety and Efficacy Study of Lipoic Acid in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: lipoic acid group;Drug: control groupSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNULLRecruiting20 Years75 YearsAll150N/AChina
4ChiCTR-IPR-15007365
2015-11-042015-11-03A Multi-center, Randomized, Double Blinding, Placebo-Controlled Clinical Trial of Dl-3-Butylphthalide in the Treatment of Amyotrophic Lateral SclerosisA Multi-center, Randomized, Double Blinding, Placebo-Controlled Clinical Trial of Dl-3-Butylphthalide in the Treatment of Amyotrophic Lateral Sclerosis amyotrophic lateral sclerosisTreatment group:to give Butylphthalide soft capsules, 2 / time, 3 times / day, fasting;Control group:to give placebo, 2 / time, 3 times / day, fasting;Peking Union Medical College HospitalNULLRecruitingBothTreatment group:147;Control group:147;China
5NCT01363401
(ClinicalTrials.gov)
February 201130/5/2011Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral SclerosisAn Open-label, Phase I/II Trial for Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis;ALSBiological: HYNR-CS inj;Other: Control groupCorestem, Inc.NULLCompleted25 Years75 YearsAll72Phase 1;Phase 2Korea, Republic of

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
28 / 4,183 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000036094
2021-01-012020-08-21A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Duhuo Jisheng Tang in The Treatment of Rheumatoid Arthritis by Regulating Lymphatic DrainageA Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Duhuo Jisheng Tang in The Treatment of Rheumatoid Arthritis by Regulating Lymphatic Drainage Rheumatoid ArthritisExperimental group:Duhuo Jisheng Tang, MTX as base treatment.;Control group:Duhuo Jisheng Tang placebo, MTX as base treatment.;Longhua Hospital affiliated to Shanghai University of Traditional Chinese MedicineNULLPending1870BothExperimental group:60;Control group:60;China
2ChiCTR2000037008
2020-10-012020-08-26The Effect of Bushen Jiedu Tongluo Decoction in the treatment of active rheumatoid arthritis: a randomized, double-blind, controlled clinical studyThe Effect of Bushen Jiedu Tongluo Decoction in the treatment of active rheumatoid arthritis: a randomized, double-blind, controlled clinical study rheumatoid arthritisexperimental group:MTX 15mg qw po+Bushen Jiedu Tongluo Decoction Granule One dose a day, two times a day;control group:MTX 15mg qw po+placebo Granule One dose a day, two times a day;Shuguang Hospital Affiliated to Shanghai University of traditional Chinese MedicineNULLPending1880Bothexperimental group:53;control group:53;China
3ChiCTR2000037675
2020-10-012020-08-30Clinical study of Shenshi Qianghuo Dihuang Decoction in the treatment of Rheumatoid arthritis from the perspective of ''7+1''Clinical study of Shenshi Qianghuo Dihuang Decoction in the treatment of Rheumatoid arthritis from the perspective of ''7+1'' Rheumatoid arthritiscontrol group:Methotrexate;experimental group:Qianghuo Dihuang Decoction + Methotrexate;Shanghai Traditional Chinese Medicine HospitalNULLRecruitingBothcontrol group:72;experimental group:72;China
4ChiCTR2000035179
2020-08-012020-08-02The effect of the iPACK block on pain and knee function in knee flexion deformity patients after primary TKA: a double-blinded, prospective, randomized controlled trialaThe effect of the iPACK block on pain in knee flexion deformity patients after primary TKA: a double-blinded, prospective, randomized controlled trial knee osteoarthritis/ knee rheumatoid arthritisIPACK group:infiltration of 20 ml ropivacaine 0.25% between the interspace between the popliteal artery and capsule of the knee;control group:infiltration of 20ml 0.9% salinebetween the interspace between the popliteal artery and capsule of the knee;West China Hospital, Sichuan UniversityNULLPending1880BothIPACK group:40;control group:40;N/AChina
5ChiCTR2000035146
2020-08-012020-08-02The effect of the IPACK block on pain after primary TKA in different levels of knee flexion deformity patients: a prospective, cohort trialThe effect of the IPACK block on pain after primary TKA in different levels of knee flexion deformity patients: a prospective, cohort trial knee osteoarthritis/ knee rheumatoid arthritisThe knee flexion deformities of different degrees were divided into different groups, and the patients without knee flexion deformity were the control group:Under the guidance of ultrasound, 20 ml 0.25% ropivacaine was injected between popliteal artery and knee joint capsule;West China Hospital, Sichuan UniversityNULLPending1880BothThe knee flexion deformities of different degrees were divided into different groups, and the patients without knee flexion deformity were the control group:80;N/AChina
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6ChiCTR2000030247
2020-03-012020-02-26Clinical study of guanxining tablet in the treatment of rheumatoid arthritis with cardiovascular damageClinical study of guanxining tablet in the treatment of rheumatoid arthritis with cardiovascular damage Systemic lupus erythematosusexperimental group:Integrative MTX with Guanxinning;control group:MTX;Zhejinag University of f Chinese MedicineNULLRecruitingBothexperimental group:30;control group:30;China
7ChiCTR1900026257
2019-09-282019-09-28A Randomized, Double-Blind Clinical Trial for Effect of Wisconsin Ginseng (Panax quinquefolius) in Improvement of Rheumatoid Arthritis Associated FatigueEfficacy, dose comparison, and safety of Wisconsin Ginseng (Panax quinquefolius) in patients with rheumatoid arthritis associated fatigue: Three-arm parallel, multicenter, randomized, double-blind, placebo-controlled, phase 2 trial Rheumatoid arthritis (RA)High-dose experimental group :6000mg Wisconsin ginseng (Panax quinquefolius) herb intervention: 3000mg, orally, twice daily (bid) Capsule (6 capsules / 500mg) ;Low-dose experimental group:3000mg Wisconsin ginseng (Panax quinquefolius) herb intervention: 1500mg, orally, twice daily (bid) Capsule (3 capsules / 500mg); 3000mg Placebo: 1500mg, orally, twice daily (bid) Capsule (3 capsules / 500mg) ;Control group :6000mg Placebo: 3000mg, orally, twice daily (bid) Capsule (6 capsules / 500mg) ;Zhejiang Provincal Hospital of TCMNULLPending1870BothHigh-dose experimental group :30;Low-dose experimental group:30;Control group :30;Phase 2China
8JPRN-jRCTs071190001
29/08/201902/04/2019Continuation of certolizumab pegol with Or Without MTX in RA patients achieving sustained remissioN and low disease activityContinuation of certolizumab pegol with Or Without MTX in RA patients achieving sustained remissioN and low disease activity - CROWN study Rheumatoid arthritisPatients retaining LDA with the combination of CZP and MTX are randomized to two groups consisting of patients who continue MTX at the same doses or discontinue MTX. The effects of both groups are compared 1 year after starting study.

Control group
combination therapy with subcutaneous CZP (200 mg in every 2 weeks or 400 mg in every 4 weeks) and oral MTX (at the same dose before starting the protocol treatment) given for 52 weeks of the protocol treatment, or until the time of discontinuation.

Intervention group
monotherapy with CZP (200 mg in every 2 weeks or 400 mg in every 4 weeks) given for 52 weeks of the protocol treatment, or until the time of discontinuation.

The discontinuation criteria for the study are as follows:
1) When subjects requested to discontinue the treatment
2) When the principal investigator or subinvestigator considered that the therapy should be discontinued due to adverse (drug) events
3) When a subject turned out not to fulfil the inclusion criteria or meets the exclusion criteria after starting the study
4) When RA relapses, defined as SDAI over 11, were observed at two consecutive visits
5) When the principal investigator or subinvestigator considered continuation of the study is inappropriate for reasons other than above
Miyazaki YusukeTanaka YoshiyaRecruiting>= 16age oldNot applicableBoth150Phase 4Japan
9ChiCTR1900024902
2019-08-012019-08-03A randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritisA randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritis Rheumatoid ArthritisExperimental group:Traditional Chinese medicine (Yi-Shen Tong-Bi Tang);Positive control group:Methotrexate;The First Affiliated Hospital of Guangzhou University of Traditional Chinese MedicineNULLPending1865BothExperimental group:50;Positive control group:50;N/AChina
10ChiCTR2000032534
2019-05-152020-05-01Pharmacoeconomic evaluation of Anbainuo in the treatment of moderate to severe rheumatoid arthritis - a single center, control studyPharmacoeconomic evaluation of Anbainuo in the treatment of moderate to severe rheumatoid arthritis - a single center, control study Rheumatoid arthritisExperimental group:Anbainuo plus methotrexate;Control group:Methotrexate, salazopyridine, leflumide, hydroxychloroquine;The Affiliated ZhuZhou Hospital Of XiangYa School Of Medicine CSU.NULLCompletedBothExperimental group:47;Control group:43;Phase 4China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11ChiCTR1800019277
2018-11-012018-11-02The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patientsThe Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients Rheumatoid ArthritisControl group:MTX;Treatment group 1:Zoledronate Acid(ZA);Treatment group 2:MTX+Zoledronate Acid;Shanghai Traditional Medicine University Affiliated Guanghua HospitalNULLRecruiting1865BothControl group:22;Treatment group 1:22;Treatment group 2:22;China
12EUCTR2017-004226-15-DK
(EUCTR)
26/10/201805/01/2018 Can-Art Effect and safety of using Canabis derivatives for the treatment of pain in patients with inflammatory Arthritis, such as reumatoid arthritis and ankylosing spondylitis, the latter being a type of arthritis that causes a long term inflammation of the joints of the spine. A randomized, double blinded, placebo controlled trial, i.e. in this drug trial, a control group is given a placebo while another group is given the Cannabis derivative being studied. CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A randomized, double blinded, placebo controlled trial - Can-Art Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)
MedDRA version: 20.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 20.0;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
King Christian 10th Hospital for RheumatologyNULLNot Recruiting Female: yes
Male: yes
180Phase 2Denmark
13ChiCTR1900026079
2018-10-252019-09-20Wangbi capsule combined methotrexate tablets for treatment of Rheumatoid Arthritis: A Randomized,Double-blind,Single analog,Positive Drug Parallel-group controlled clinical studyWangbi capsule combined methotrexate tablets for treatment of Rheumatoid Arthritis: A Randomized,Double-blind,Single analog,Positive Drug Parallel-group controlled clinical study Rheumatoid ArthritisExperimental group:Wangbi capsule combined methotrexate tablets;Control group:Simulation of Wangbi capsule combined methotrexate tablets;Longhua Hospital Shanghai University of Traditional Chinese MedicineNULLRecruiting1870BothExperimental group:60;Control group:60;Phase 4China
14ChiCTR1800014872
2018-03-012018-02-12Role of parecoxib sodium in the multimodal analgesia after total knee arthroplastySafety and efficacy of parecoxib sodium in the multimodal analgesia after total knee arthroplasty: a prospective randomized controlled trial osteoarthritis or rheumatoid arthritisExperimental group:Preoperative intravenous injection of parecoxib sodium and postoperative intravenous patient-controlled analgesia;Control group:Preoperative normal saline injection and postoperative intravenous patient-controlled analgesia;Peking Union Medical College HospitalNULLPendingBothExperimental group:50;Control group:50;China
15JPRN-UMIN000031692
2018/03/0112/03/2018Efficacy and Safety of repeated administration of intravenous acetaminophen injection for pain management after total knee arthroplastyEfficacy and Safety of repeated administration of intravenous acetaminophen injection for pain management after total knee arthroplasty - Efficacy of intravenous acetaminophen injection for pain management after TKA knee osteoarthritis rheumatoid arthritisStudy group:Fentanyl sustained intravenous administration given after operation end. And use the Intravenous acetaminophen 4 times per 6 hour.Dosage is 15 mg/kg for the patient less than 50 kg in weight and 1000 mg for the patient more than 50 kg in weight.
Control group:Fentanyl sustained intravenous administration given after operation end.
Yamaguchi UniversityNULLRecruiting20years-oldNot applicableMale and Female60Not selectedJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16ChiCTR1800014404
2018-01-112018-01-11Evaluation of clinical curative effect of Bushen Quhan Wang Decoction in the treatment of kidney deficiency and cold dampness syndrome of rheumatoid arthritisEvaluation of clinical curative effect of Bushen Quhan Wang Decoction in the treatment of kidney deficiency and cold dampness syndrome of rheumatoid arthritis rheumatoid arthritistreatment group :MTX+traditional Chinese medicine ;control group :MTX;China-Japan Friendship HospitalNULLRecruiting1670Bothtreatment group :36;control group :36;China
17ChiCTR-INR-17011772
2017-06-272017-06-28The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agentsThe efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents Rheumatoid Arthritistest group:Metformin tablets, 0.25g, 3 / day, oral, atorvastatin tablets 10mg, 1 / night, oral;;Control group:Traditional DMARDs group;Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated HospitalNULLRecruiting1865Bothtest group:80;Control group:40;China
18ChiCTR-INR-16010290
2017-01-012016-12-28The research for the treatment of Rheumatoid Arthritis with Warming yang and Smoothening MeridiansThe research for the treatment of Rheumatoid Arthritis with Warming yang and Smoothening Meridians Rheumatoid Arthritistreatment group:MTX+Wen yang tong luo granule;control group:MTX;The First Hospital Affiliated to Henan University of TCMNULLRecruiting1865Bothtreatment group:180;control group:180;China
19ChiCTR-IPR-16009029
2016-11-012016-08-15Clinical Study of the Bone Protection Effect of Biqi Capsule for Treatment of Rheumatoid ArthritisClinical Study of the Bone Protection Effect of Biqi Capsule for Treatment of Rheumatoid Arthritis Rheumatoid arthritisRA:the experimental group:MTX 10-15mg po qw+BiQi Capsule, 1.2g po bid;RA:the control group:MTX 10-15mg po qw+LEF, 10mg, po, bid;OA:The traditional Chinese group:BiQi Capsule, 1.2g po bid+Celecoxib capsules 0.2g po take as needed;OA:The western medicine control group:Calcitriol Soft Capsules 0.25ug, po, bid+Celecoxib capsules 0.2g po take as needed;Guangdong Provincial Hospital of Chinese MedicineNULLPending1865BothRA:the experimental group:60;RA:the control group:60;OA:The traditional Chinese group:60;OA:The western medicine control group:60;China
20ChiCTR-IPR-16008793
2016-07-152016-06-10A multi center, randomized, double blind, positive parallel controlled clinical study of Zhengqing Fengtongning sustained release tablets in the treatment of rheumatoid arthritisA multi center, randomized, double blind, positive parallel controlled clinical study of Zhengqing Fengtongning sustained release tablets in the treatment of rheumatoid arthritis Rheumatoid arthritisexperimental group:ZHENGQING FENGTONGNING sustained release tablets; control group:methotrexate;The combined treatment group:ZHENGQING FENGTONGNING sustained release tablets combine methotrexate;The First Affiliated Hospital of Third Military Medical UniversityNULLRecruiting1875Bothexperimental group:80; control group:80;The combined treatment group:80;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21ChiCTR1800014846
2014-12-012018-02-09Effect of preemptive analgesia with parecoxib sodium on multimodal analgesia in primary unilateral total hip arthroplastyEffect of preemptive analgesia with parecoxib sodium on multimodal analgesia in primary unilateral total hip arthroplasty: A prospective randomized double-blind controlled trial osteonecrosis of the femoral head, femoral neck fracture, developmental dysplasia of hip, osteoarthritis, rheumatoid arthritis or ankylosing spondylitisExperiment group:preoperative intravenous parecoxib sodium and postoperative intravenous parecoxib sodium and patient-controlled analgesia;Control Group:preoperative intravenous pure 0.9% saline and postoperative intravenous parecoxib sodium and patient-controlled analgesia;Peking Union Medical College HospitalNULLCompletedBothExperiment group:50;Control Group:50;China
22ChiCTR1900026116
2014-06-012019-09-22The efficacy and safety of low-dose glucocorticoids combined withmethotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: a randomized, double-blinded, controlled trialThe efficacy and safety of low-dose glucocorticoids combined withmethotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: a randomized, double-blinded, controlled trial rheumatoid arthritisExperimental group:Prednisone+methotrexate+Hydrochloroquine;control group:placebo+methotrexate+Hydrochloroquine;Central Hospital of JinhuaNULLCompleted2173BothExperimental group:40;control group:40;Phase 4China
23ChiCTR1800019290
2014-01-012018-11-03The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patientsThe Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients Rheumatoid ArthritisControl group:MTX;Treatment group 1:ZA;Treatment group 2:MTX+ZA;Xiao LianboNULLCompleted1865BothControl group:22;Treatment group 1:22;Treatment group 2:22;2 (Phase 2 study)China
24ChiCTR-ONRC-13003578
2013-09-012013-09-09Agkistrodon different formulations inflammatory and analgesic effects on rheumatoid arthritis clinical studyAgkistrodon different formulations inflammatory and analgesic effects on rheumatoid arthritis clinical study Rheumatoid arthritisThe water decoction group of Agkistrodon:Taking the water decoction of Agkistrodon;Agkistrodon liquor:Taking Agkistrodon liquor agents;Agkistrodon pulvis:Taking the Agkistrodon pulvis;Control group:Taking placebo;Zhejiang Chinese Medical UniversityNULLCompleted1865BothThe water decoction group of Agkistrodon:30;Agkistrodon liquor:30;Agkistrodon pulvis:30;Control group:30;I (Phase 1 study)China
25JPRN-UMIN000006702
2012/02/0111/11/2011A parallel group, randomized clinical trial on the efficacy and safety of intensive treatment strategy with MTX as the anchor-drug in patients with active early rheumatoid Arthritis rheumatoid arthritisIntensive treatment group
Period: 24 weeks
In the intensive treatment group, a patient starts treatment with MTX at 8mg/week. Dosage is increased to 0.25mg/kg/week by week 8 and is further increased to his or her maximum tolerable dosage by week 12. The maximum tolerable dosage is maintained until week 24. If a patient shows inadequate response to MTX and does not achieve SDAI(simplified disease activity index)emission or CDAI (linical disease activity index)remission by week 16, additional treatment with tacrolimus, bucillamine, sarazosulfapyridine, or biologics will be started as scheduled in the protocol.
After week 24, both groups receive treatments by attending rheumatologists'discretion and are followed until week 72.
Conventional treatment group
Period: 24 weeks
In the control group, a patient starts treatment with MTX, tacrolimus, bucillamine, sarazosulfapyridine, or biologics by attending rheumatologists' discretion by week 24. Biologics are allowed on and after week 12. After week 24, both groups receive treatments by attending rheumatologists'discretion and are followed until week 72.
Tokyo Medical and Dental UniversityDepartment of PharmacovigilanceComplete: follow-up continuing20years-old70years-oldMale and Female290Not applicableJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26ChiCTR-TRC-10001014
2010-09-012010-08-30Randomized Controlled Study to Evaluate the Clinical Outcomes of Rheumatoid Arthritis Treated with Method of Activating Blood Circulation by Removing Blood StasisRandomized Controlled Study to Evaluate the Clinical Outcomes of Rheumatoid Arthritis Treated with Method of Activating Blood Circulation by Removing Blood Stasis Rheumatoid Arthritis;M06.991Group A:observation group: Leflunomide Tablets, from the first day to the third day, 50mg, qd, po, then 20mg, qd, po. Ligustrazine Powder-Needle, 0.12g, solubling in 5% GS/NS 100ml, qd, iv, in 30 to 60 minutes. ;Group B:control group: Leflunomide Tablets, from the first day to the third day, 50mg, qd, po, then 20mg, qd, po. ;Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical SciencesNULLCompleted1865BothGroup A:60;Group B:60;I (Phase 1 study)China
27NCT02779114
(ClinicalTrials.gov)
January 200916/5/2016RETRO (REduction of Therapy in RA Patients in Ongoing Remission)A Phase 3, Multicenter, Randomized, Open, Prospective, Controlled, Parallel Group Study of Reduction of Therapy in Patients With Rheumatoid Arthritis in Ongoing Remission.Rheumatoid ArthritisDrug: Control group;Other: Reduction group 1;Other: Reduction group 2University of Erlangen-Nürnberg Medical SchoolNULLRecruiting18 YearsN/ABoth318Phase 3Germany
28ChiCTR-TRC-10000850
2008-10-012010-04-26Phase III clinical trial of Iguratimodin rheumatoid arthritisPhase III clinical trial of Iguratimodin rheumatoid arthritis rheumatoid arthritis3:Experimental group: Iguratimod tablet, nimesulide dummy tablet; positive control group: taking nimesulide and Iguratimod dummy tablet; placebo group: taking Iguratimod dummy tablet and nimesulide dummy tablet. ;Anhui Medical UniversityNULLCompleted1865Both3:600;3 (Phase 3 study)China

70. Spinal stenosis    [ 91 clinical trials,   195 drugs,   (DrugBank: 54 drugs),   60 drug target genes,   85 drug target pathways]
Searched query = "Spinal stenosis", "Extensive spinal canal stenosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 91 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000030881
2018/01/1818/01/2018Dietary supplementation in patients following lumbar spine surgery: a randomized controlled trialDietary supplementation in patients following lumbar spine surgery: a randomized controlled trial - Dietary supplementation in patients following lumbar spine surgery lumbar spinal stenosisIntervention group
Twice-daily ingestion of amino acids supplementation for 3 weeks after spinal surgery (100kcal, protein 10g)
Postoperative rehabilitation for 3 weeks
Control group
Twice-daily ingestion of placebo (non amino acids) supplementation for 3 weeks after spinal surgery (100kcal, protein 0g )
Postoperative rehabilitation for 3 weeks
Wakayama Medical UniversityNULLRecruiting50years-old90years-oldMale and Female80Not selectedJapan
2NCT02902380
(ClinicalTrials.gov)
September 27, 20166/9/2016The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal SurgerySpinal StenosisDrug: dexmedetomidine group;Drug: control groupYonsei UniversityNULLCompleted20 Years70 YearsAll52N/AKorea, Republic of
3ChiCTR-TRC-13003639
2012-09-132013-09-07The application of Analgesia Nociception Index guided Remifentanil administration during general anesthesia for Spinal SurgeryThe application of Analgesia Nociception Index guided Remifentanil administration during general anesthesia for Spinal Surgery Lumbar spinal stenosis and/or lumbar intervertebral disc herniationANI group:ANI guide the administration of remifentanil;control group:remifentanil was adapted by Anaesthesiologist corresponding to clinical experiences ;Peking University Third HospitalNULLCompleted1870BothANI group:30;control group:30;China